Kymera Therapeutics Files 8-K

TL;DR

Kymera Therapeutics filed an 8-K on 7/8/24 covering various disclosures.

AI Summary

Kymera Therapeutics, Inc. filed an 8-K on July 8, 2024, reporting on various events. The filing includes information related to Regulation FD disclosures, other events, and financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Watertown, Massachusetts.

Why It Matters

This 8-K filing provides updates on company events and disclosures, which are important for investors to understand the latest developments at Kymera Therapeutics.

Risk Assessment

Risk Level: low — This filing is a routine 8-K report and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

• Kymera Therapeutics, Inc. (company) — Registrant
• July 8, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• Watertown, Massachusetts (location) — Address of principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value per share KYMR The Nasdaq

Filing Documents

• d863965d8k.htm (8-K) — 26KB
• d863965dex991.htm (EX-99.1) — 11KB
• g863965g0707225347434.jpg (GRAPHIC) — 3KB
• 0001193125-24-176312.txt ( ) — 164KB
• kymr-20240708.xsd (EX-101.SCH) — 3KB
• kymr-20240708_lab.xml (EX-101.LAB) — 18KB
• kymr-20240708_pre.xml (EX-101.PRE) — 11KB
• d863965d8k_htm.xml (XML) — 4KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2024 KYMERA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-39460 81-2992166 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) Kymera Therapeutics, Inc. 500 North Beacon Street , 4th Floor Watertown , Massachusetts 02472 (Address of principal executive offices, including zip code) (857) 285-5300 (Registrant's telephone number, including area code) Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trade Symbol(s) Name of each exchange on which registered Common Stock, $0.0001 par value per share KYMR The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 ( 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( 240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item7.01 Regulation FD Disclosure. On July 8, 2024, Kymera Therapeutics, Inc. (the "Company") issued a press release, a copy of which is furnished herewith as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing. Item8.01 Other Events. On July 8, 2024, the Company announced that following a review of preliminary KT-474 safety and efficacy data by an Independent Data Review Committee, Sanofi has informed the Company that it intends to expand the ongoing Hidradenitis Suppurativa and Atopic Dermatitis Phase 2 trials to more rapidly progress towards pivotal studies. Item9.01. Exhibits (d) Exhibits Exhibit No. Description 99.1 Press release issued by Kymera Therapeutics, Inc. on July 8, 2024, furnished herewith. 104 Cover Page Interactive Data (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Kymera Therapeutics, Inc. Date: July 8, 2024 By: /s/ Nello Mainolfi Nello Mainolfi, Ph.D. President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR